05 October 2017
Washington DC
Reporter: Barney Dixon

Allergan Restasis deal to be investigated


Allergan’s patent deal with the Saint Regis Mohawk tribe is to be investigated by Congress after senators and drug manufacturers complained that the move was anti-competitive.

In a letter to Allergan’s CEO on 3 October, the Committee on Oversight and Government Reform described the patent deal in which Allergan transferred its entire portfolio of Restasis dry eye treatment patents to the Native American tribe, as an “unconventional maneuver”.

The committee requested that Allergan cooperate with a Congressional evaluation by disclosing all terms and documents relating to the agreement.

Bob Bailey, chief legal officer at Allergan, previously described the move as a “sophisticated opportunity to strengthen the defense of our Restasis intellectual property in the upcoming IPR proceedings before the US Patent Trial and Appeal Board”.

He added: “Allergan evaluated this approach closely, with expert counsel in patent and sovereign immunity law.”

The committee said the sovereign status of Native American tribes added complexity to the contesting status of the patents in question, “because tribes may be immune from the legal claims generic drug makers use to challenge patents and bring less costly drugs to market more quickly”.

It added: “The implications of Allergan's patent transfer raise questions for Congress as the exchange may impair competition across the pharmaceutical industry and ultimately dissuade companies from pursuing less-costly generic alternatives to brand drugs.”

Last week, US senators Margaret Hassan, Sherrod Brown, Robert Casey and Richard Blumenthal penned a letter to the US Judiciary committee describing Allergan’s deal as “a blatantly anti-competitive attempt to shield its patents from review and keep drug prices high”.

They added: “Allergan’s actions directly circumvent the inter partes review process, established by Congress in the America Invents Act of 2011. We are deeply concerned with the numerous patent law and anti-competitive implications of Allergan’s deal, which harm patients’ ability to afford medications.”

“We believe that sovereign immunity is a fundamental precept of our legal structure and that there should be parity among States and Tribes,” they said, “Companies should not be allowed to pay States and Tribes simply to invoke their sovereign immunity, and companies like Allergan should not be allowed to exploit sovereign immunity at the expense of patients.”

More news
The latest news from IPPro Patents
Join Our Newsletter

Sign up today and never
miss the latest news or an issue again

Subscribe now
Patent perception must shift, says Schecter
13 December 2017 | London | Reporter: Barney Dixon
Public perception must shift if the US is to find feasible solutions to patent abuse, according to chief patent counsel at IBM Manny Schecter
Patent owners winning in IPR
12 December 2017 | New York | Reporter: Barney Dixon
Patent owners are winning more than losing in IPR proceedings, according to a study from law firm Fitzpatrick, Cella, Harper & Scinto
High tech companies weigh in on Allergan deal
11 December 2017 | Washington DC | Reporter: Barney Dixon
Tech companies have argued that Allergan should not be allowed to circumvent the inter partes review process with its controversial patent deal with the Saint Regis Mohawk Tribe
BlackBerry to pay $137 million to Nokia
08 December 2017 | Waterloo | Reporter: Barney Dixon
BlackBerry will pay $137 million to Nokia after the International Chamber of Commerce’s International Court of Arbitration ruled against the company in a patent licensing dispute
ILO ruling “vote of no confidence” for Battistelli, says CSC
07 December 2017 | Munich | Reporter: Barney Dixon
In an open letter to the EPO’s heads of delegations, the CSC said that it interpreted the ILO’s decision as a “massive vote of no confidence in the president of the EPO"
China world’s top patent filer in 2016
07 December 2017 | Geneva | Reporter: Barney Dixon
China has emerged as the top patent filer in the world, accounting for nearly all of the 8 percent growth in patent applications in 2016
EPO president’s impartiality questioned at ILO
06 December 2017 | Geneva | Reporter: Barney Dixon
The International Labour Organisation has questioned the impartiality of EPO president Benoît Battistelli, in two tribunal decisions concerning an EPO employee, and found that there was a conflict of interest on the part of the president